Fulcrum Therapeutics

Fulcrum Therapeutics logo
🇺🇸United States
Ownership
Public
Established
2016-01-01
Employees
76
Market Cap
$552.5M
Website
http://www.fulcrumtx.com

Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)

First Posted Date
2022-05-31
Last Posted Date
2024-12-02
Lead Sponsor
Fulcrum Therapeutics
Target Recruit Count
260
Registration Number
NCT05397470
Locations
🇺🇸

University of California Irvine, Irvine, California, United States

🇺🇸

University of California Los Angeles (UCLA), Los Angeles, California, United States

🇺🇸

Kennedy Krieger Institute, Baltimore, Maryland, United States

and more 30 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058

First Posted Date
2021-12-27
Last Posted Date
2024-11-21
Lead Sponsor
Fulcrum Therapeutics
Target Recruit Count
70
Registration Number
NCT05169580
Locations
🇺🇸

Queens Hospital Cancer Center, Jamaica, New York, United States

🇺🇸

University of Texas Houston, Houston, Texas, United States

🇺🇸

University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States

and more 16 locations

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

First Posted Date
2021-08-12
Last Posted Date
2021-11-12
Lead Sponsor
Fulcrum Therapeutics
Target Recruit Count
18
Registration Number
NCT05002231
Locations
🇺🇸

PPD Phase I Clinic, Austin, Texas, United States

Safety, Tolerability and Pharmacokinetics of FTX-6058

First Posted Date
2020-10-14
Last Posted Date
2022-12-12
Lead Sponsor
Fulcrum Therapeutics
Target Recruit Count
109
Registration Number
NCT04586985
Locations
🇺🇸

Altasciences Clinical Kansas, Inc. - Healthy Adults Subjects Only, Overland Park, Kansas, United States

🇺🇸

Atlanta Center for Medical Research - Sickle Cell Subjects Only, Atlanta, Georgia, United States

Losmapimod Safety and Efficacy in COVID-19

First Posted Date
2020-08-13
Last Posted Date
2024-03-13
Lead Sponsor
Fulcrum Therapeutics
Target Recruit Count
52
Registration Number
NCT04511819
Locations
🇲🇽

Nuevo Hospital Civil de Guadalajara, Guadalajara, JC, Mexico

🇵🇪

Hospital Nacional Carlos Alberto Seguín Escobedo - EsSalud Arequipa, Arequipa, AR, Peru

🇺🇸

University of Miami, Miami, Florida, United States

and more 13 locations

Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)

First Posted Date
2020-02-11
Last Posted Date
2024-12-02
Lead Sponsor
Fulcrum Therapeutics
Target Recruit Count
76
Registration Number
NCT04264442
Locations
🇪🇸

Hospital UiP La Fe, Valencia, Spain

🇫🇷

CHU de NICE- CHU pasteur2, Nice, France

🇪🇸

Hospital de la Sta Creu i St Pau, Barcelona, Spain

and more 14 locations

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

First Posted Date
2019-07-01
Last Posted Date
2024-07-10
Lead Sponsor
Fulcrum Therapeutics
Target Recruit Count
80
Registration Number
NCT04003974
Locations
🇺🇸

University of California Irvine, Irvine, California, United States

🇺🇸

Kennedy Krieger Institute, Baltimore, Maryland, United States

🇺🇸

University of Washinton Medical Center, Seattle, Washington, United States

and more 14 locations

Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With Extension

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2019-07-01
Last Posted Date
2024-12-02
Lead Sponsor
Fulcrum Therapeutics
Target Recruit Count
14
Registration Number
NCT04004000
Locations
🇳🇱

Radboud University Medical Center, Nijmegen, Netherlands

© Copyright 2024. All Rights Reserved by MedPath